Oscar Chien, MD
Geriatric Medicine · San Gabriel, CANPI 1679675904
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $155,207 of the $208,240 with a category attached, or 74.5%. It is spread thinly across 60 manufacturers, the largest accounting for just 19.6%. Reporting peaked in 2019 at $76,106 and has fallen 81.8% since, to $13,874 in 2025. Among geriatric medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,253 payments — averaging $166.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$41K
- AbbVie$37K
- Radius Health, Inc.$23K
- Amarin Pharma, Inc.$18K
- Gilead$15K
- Sumitomo Pharma America, Inc.$12K
- plus $62K from 54 others
What the payments were for
- Consulting fees$3,7002%
- Speaking & faculty fees$155,20775%
- Travel & lodging$12,6016%
- Food & beverage$36,07317%
- Education$6590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$208,240 in reported general payments places this provider in the 95th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 875 | $595,880 |
| CreonLipase/Protease/Amylase | 291 | $494,721 |
| KerendiaFinerenone | 639 | $474,292 |
| FarxigaDapagliflozin Propanediol | 693 | $435,112 |
| VascepaIcosapent Ethyl | 847 | $331,547 |
| ProliaDenosumab | 198 | $329,208 |
| LinzessLinaclotide | 517 | $311,192 |
| TradjentaLinagliptin | 495 | $279,159 |
| JanuviaSitagliptin Phosphate | 390 | $221,249 |
| Austedo XrDeutetrabenazine | 20 | $189,525 |
| VemlidyTenofovir Alafenamide | 108 | $165,825 |
| EliquisApixaban | 305 | $163,501 |
| RybelsusSemaglutide | 125 | $153,633 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 61 | $151,846 |
| GemtesaVibegron | 252 | $145,053 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $992 | $972,8361,512 claims |
| AbbVieCreon, Linzess, Restasis, Namzaric | $36,829 | $933,138990 claims |
| AmgenProlia, Evenity (2 Syringes) | $40,792 | $481,054259 claims |
| BayerKerendia | $1,236 | $474,292639 claims |
| AstraZenecaFarxiga | $3,175 | $435,112693 claims |
| MerckJanuvia | $265 | $221,249390 claims |
| Novo NordiskRybelsus, Ozempic | $1,440 | $206,864177 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,849 | $189,52520 claims |
| GileadVemlidy | $15,398 | $165,825108 claims |
| PfizerEliquis | $552 | $163,501305 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $11,691 | $145,053252 claims |
| Johnson & JohnsonXarelto | $9,993 | $123,305247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in San Gabriel
- Robert FeldmanLaguna Hills$1.2M
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
- Wayne ChenLos Angeles$40K
- Vincent HoLancaster$32K
- Kathryn SewellSan Francisco$26K
- Stephen HenryPasadena$25K
- Chaewon SongGarden Grove$21K
- Douglas ZhangSan Leandro$20K
- Hermenegildo AngelesDaly City$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.